Literature DB >> 25503899

[Structure of biobanks for urological research].

G Hatiboglu1, J Huber, E Herpel, I V Popeneciu, J Nyarangi-Dix, D Teber, B A Hadaschik, S Pahernik, S Duensing, M Hohenfellner.   

Abstract

Biomedical research plays an important role in the development of novel diagnostic procedures, drugs and treatment strategies with regard to cancerous and chronic inflammatory diseases. Biobanks are essential tools in this process. The complex structures and benefits of biobanks are presented in this article.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25503899     DOI： 10.1007/s00120-014-3722-y

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


  30 in total

1.  DNA banking for epidemiologic studies: a review of current practices.

Authors:  Karen Steinberg; Jeanne Beck; Deborah Nickerson; Montserrat Garcia-Closas; Margaret Gallagher; Michele Caggana; Yvonne Reid; Mark Cosentino; Jay Ji; Delene Johnson; Richard B Hayes; Marie Earley; Fred Lorey; Harry Hannon; Muin J Khoury; Eric Sampson
Journal:  Epidemiology       Date:  2002-05       Impact factor: 4.822

2.  Netherlands Twin Register: from twins to twin families.

Authors:  Dorret I Boomsma; Eco J C de Geus; Jacqueline M Vink; Janine H Stubbe; Marijn A Distel; Jouke-Jan Hottenga; Danielle Posthuma; Toos C E M van Beijsterveldt; James J Hudziak; Meike Bartels; Gonneke Willemsen
Journal:  Twin Res Hum Genet       Date:  2006-12       Impact factor: 1.587

3.  Small renal cell carcinoma: oncological outcome with tumour size.

Authors:  Sascha Pahernik; Johannes Huber; Jesco Pfitzenmaier; Axel Haferkamp; Markus Hohenfellner
Journal:  Scand J Urol Nephrol       Date:  2011-10-24

Review 4.  New concepts of biobanks--strategic chance for uro-oncology.

Authors:  Peter J Goebell; Manuel M Morente
Journal:  Urol Oncol       Date:  2010 Jul-Aug       Impact factor: 3.498

5.  Pathological upstaging detected in radical cystectomy procedures is associated with a significantly worse tumour-specific survival rate for patients with clinical T1 urothelial carcinoma of the urinary bladder.

Authors:  Matthias May; Patrick J Bastian; Sabine Brookman-May; Maximilian Burger; Christian Bolenz; Lutz Trojan; Maurice S Michel; Edwin Herrmann; Christian Wülfing; Arne Tiemann; Stefan C Müller; Jörg Ellinger; Alexander Buchner; Christian G Stief; Derya Tilki; Wolf F Wieland; Christian Gilfrich; Thomas Höfner; Markus Hohenfellner; Axel Haferkamp; Jan Roigas; Mario Zacharias; Sven Gunia; Hans-Martin Fritsche
Journal:  Scand J Urol Nephrol       Date:  2011-03-10

6.  Perinephric and renal sinus fat infiltration in pT3a renal cell carcinoma: possible prognostic differences.

Authors:  Jens Bedke; Stephan Buse; Maria Pritsch; Stephan Macher-Goeppinger; Peter Schirmacher; Axel Haferkamp; Markus Hohenfellner
Journal:  BJU Int       Date:  2008-12-08       Impact factor: 5.588

7.  Decoy receptor 3 is a prognostic factor in renal cell cancer.

Authors:  Stephan Macher-Goeppinger; Sebastian Aulmann; Nina Wagener; Benjamin Funke; Katrin E Tagscherer; Axel Haferkamp; Markus Hohenfellner; Sunghee Kim; Frank Autschbach; Peter Schirmacher; Wilfried Roth
Journal:  Neoplasia       Date:  2008-10       Impact factor: 5.715

8.  Prognostic factors influencing long-term survival of patients undergoing nephron-sparing surgery for nonmetastatic renal-cell carcinoma (RCC) with imperative indications.

Authors:  Axel Haferkamp; Martin Kurosch; Maria Pritsch; Gencay Hatiboglu; Stephan Macher-Goeppinger; Jesco Pfitzenmaier; Sascha Pahernik; Nina Wagener; Markus Hohenfellner
Journal:  Ann Surg Oncol       Date:  2009-12-01       Impact factor: 5.344

9.  Endogenous BTG2 expression stimulates migration of bladder cancer cells and correlates with poor clinical prognosis for bladder cancer patients.

Authors:  N Wagener; J Bulkescher; S Macher-Goeppinger; I Karapanagiotou-Schenkel; G Hatiboglu; M Abdel-Rahim; H Abol-Enein; M A Ghoneim; P J Bastian; S C Müller; A Haferkamp; M Hohenfellner; F Hoppe-Seyler; K Hoppe-Seyler
Journal:  Br J Cancer       Date:  2013-01-08       Impact factor: 7.640

10.  Expression of inhibitor of apoptosis protein Livin in renal cell carcinoma and non-tumorous adult kidney.

Authors:  N Wagener; I Crnković-Mertens; C Vetter; S Macher-Göppinger; J Bedke; E F Gröne; H Zentgraf; M Pritsch; K Hoppe-Seyler; S Buse; A Haferkamp; F Autschbach; M Hohenfellner; F Hoppe-Seyler
Journal:  Br J Cancer       Date:  2007-10-30       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.